352209-87-1

Basic information

• Product Name: Benzenesulfonic acid, 4-butoxy-, sodium salt
• CAS NO: 352209-87-1
• Molecular Formula: C10H14O4S.Na
• Molecular Weight: 252.267
• Mol File: 352209-87-1.mol

Chemical Properties

• CAS DataBase Reference: Benzenesulfonic acid, 4-butoxy-, sodium salt(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenesulfonic acid, 4-butoxy-, sodium salt(352209-87-1)
• EPA Substance Registry System: Benzenesulfonic acid, 4-butoxy-, sodium salt(352209-87-1)

Safety Data

• Hazardous Substances Data: 352209-87-1(Hazardous Substances Data)

Upstream product

• 109-65-9 1-bromo-butane 
• 825-90-1 sodium p-hydroxybenzenesulfonate 

Downstream Products

• 880139-14-0 N-(2-(1H-indol-3-yl)ethyl)-4-butoxybenzenesulfonamide 
• 1138-56-3 4-butoxybenzene-sulfonyl chloride 

Relevant articles and documents

CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme ceramide galactosyltransferase (CGT), such as, for example, lysosomal storage diseases. Examples of lysosomal storage diseases include, for example, Krabbe disease and Metachromatic Leukodystrophy.

Design and bio-evaluation of indole derivatives as potent Kv1.5 inhibitors

Atrial fibrillation (AF) is one of the common arrhythmias that threaten human health. Kv1.5 potassium channel is reported as an efficacious and safe target for the treatment of AF. In this paper, we designed and synthesized three series of compounds through modifying the lead compound RH01617 that was screened out by the pharmacophore model we reported earlier. All of the compounds were evaluated by the whole-patch lamp technology and most of them possessed potent inhibitory activities against Kv1.5. Compounds IIIi and IIIl were evaluated for the target selectivity as well as the pharmacodynamic effects in an isolated rat model. Due to the promising pharmacological behavior, compound IIIl deserves further pharmacodynamic and pharmacokinetic evaluations.

Method for preparing alpha-sulfonyl hydroxamic acid derivatives

Compounds of the formula: that can be important as matrix metalloproteinase (MMP) and TNF-alpha converting enzyme (TACE) inhibitors, phosphodiesterase inhibitors, renin inhibitors, antithrombotics, and 5-lipoxygenase inhibitors are prepared by novel methods of the present invention.